DSDorota Suszek

Dorota Suszek

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dorota Suszek has a total of 48 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A novel approach to cardiovascular events in patients with systemic lupus erythematosus: risk factor assessment and treatment analysis

    by Dorota Suszek, Magdalena Popławska, Jakub Prośniak, Katarzyna Siemieniec, Karolina Przeniosło, Weronika Wallach, Monika Żybowska-Męczyńska, Klaudia Ostrowicz, Anna Rzewuska-Fijałkowska, Bożena Targońska -Stępniak

    Systemic lupus erythematosus (SLE) patients have a significantly increased risk of developing cardiovascular disease (CVD). Despite the implementation of preventive measures and treatment of lipid disorders, as well as reduced use of glucocorticoids, CVD remains one of the leading causes of death in this patient group. It is crucial to develop an appropriate CVD risk assessment strategy that considers the distinctive characteristics of this patient population. This paper provides a comprehensive analysis of the methods used to assess CVD risk in SLE patients. It also presents effective strategies for the reduction of the effects of traditional and non-traditional risk factors for atherosclerosis.


  • Fatal case of pancreatic panniculitis and polyarthritis due to pancreatic neuroendocrine tumor: a case report and review of literature

    by Dorota Suszek, Ewa Wielosz, Mateusz Suszek, Maksymilian Seweryn, Natalia Wilczek, Kacper Niewęgłowski, Klaudia Miller, Bożena Targońska-Stępniak

    Pancreatic panniculitis (PP) and arthritis may be extrapancreatic manifestations of pancreatic disease. The triad of pancreatic disease, panniculitis and polyarthritis, described in the literature as the PPP syndrome, is sometimes observed in patients with acute or chronic pancreatitis, pancreatic cancer or neuroendocrine tumors (NETs). We present a 60-year-old man with polyarthritis and clinically aggressive PP of the limbs. Computed tomography showed a large tumor in the uncinate process of the pancreas and multiple metastatic lesions in the liver and lungs. The skin nodules developed before the diagnosis of the occult pancreatic tumor and metastases. Biopsy of the skin nodules was performed and showed lobular panniculitis. In addition, immunopathology of the liver metastasis showed NET, a rare pathological variant. The skin lesions immediately spread to the upper limbs with extensive ulceration and necrosis, accompanied by high serum lipase levels. The patient died 4 months after the initial development of the skin lesion. PPP syndrome is a rarely recognized clinical entity. The present case report and literature review highlight the key clinical features of PPP syndrome. The absence of general or abdominal symptoms and skin changes mimicking other forms of panniculitis may lead to delayed diagnosis. It is important to broaden the diagnostic work-up for pancreatic disease in patients presenting with panniculitis and arthritis.


  • Open Access

    Usefulness in daily practice of the Systemic Lupus Erythematosus Disease Activity Index 2000 scale and the Systemic Lupus Erythematosus Disease Activity Score index for assessing the activity of systemic lupus erythematosus

    by Dorota Suszek, Maciej Dubaj, Karol Bigosiński, Aleksandra Dembowska, Marcin Kaniewski, Wiktoria Sielwanowska, Bartosz Skierkowski, Izabela Dzikowska, Julia Sieczka, Maria Majdan

    Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by high hetero­geneity of clinical manifestations and an uncertain prognosis. Although the mortality rate due to SLE has decreased significantly in recent decades, there is still a need to find good tools to measure disease activity for early detection of exacerbations and treatment planning. Over the decades, more than a dozen disease activity scales/indicators have been developed, with the SLE Disease Activity Index (SLEDAI) being the most popular. More recently, the new SLE Disease Activity Score (SLE-DAS) has been introduced. This paper compares the two methods of assessing SLE activity, and presents the relevance of these scales in pregnant SLE patients and their use in formulating definitions of remission and low disease activity. The results show that the SLEDAI and the SLE-DAS are of comparable value in assessing SLE activity and complement each other.


  • Open Access

    IgA vasculitis after COVID-19: a case-based review

    by Dorota Suszek, Anna Grzywa-Celińska, Justyna Emeryk-Maksymiuk, Adam Krusiński, Katarzyna Redestowicz, Jan Siwiec

    IgA-associated vasculitis (IgAV) known as Henoch - Schönlein purpura (HSP) disease is an inflammatory disorder of small blood vessels. It’s the most common type of systemic vasculitis in children which can be associated with the inflammatory process following infections. IgA vasculitis is a rare and poorly understood systemic vasculitis in adults. Coronavirus disease 2019 (COVID-19) has been associated with HSP in both adults and children. A 58-year-old woman was diagnosed with HSP, fulfilling the clinical criteria: palpable purpura, arthritis, hematuria. The disclosure of the HSP disease was preceded by a infection of the respiratory tract. COVID-19 infection was confirmed via the presence of IgM and IgG antibodies. This case indicates the possible role of SARS-CoV-2 in the development of HSP. The clinical course of IgAV in adults appears to be different from pediatric IgAV, especially due to higher risk of renal complications. Symptoms of the disease quickly resolved with low-dose of steroids.


  • Open Access

    Usefulness in daily practice of the Systemic Lupus Erythematosus Disease Activity Index 2000 scale and the Systemic Lupus Erythematosus Disease Activity Score index for assessing the activity of systemic lupus erythematosus

    by Dorota Suszek, Maciej Dubaj, Karol Bigosinski, Aleksandra Dembowska, Marcin Kaniewski, Wiktoria Sielwanowska, Bartosz Skierkowski, Izabela Dzikowska, Julia Sieczka, Maria Majdan

    Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by high heterogeneity of clinical manifestations and an uncertain prognosis. Although the mortality rate due to SLE has decreased significantly in recent decades, there is still a need to find good tools to measure disease activity for early detection of exacerbations and treatment planning. Over the decades, more than a dozen disease activity scales/indicators have been developed, with the SLE Disease Activity Index (SLEDAI) being the most popular. More recently, the new SLE Disease Activity Score (SLEDAS) has been introduced. This paper compares the two methods of assessing SLE activity, and presents the relevance of these scales in pregnant SLE patients and their use in formulating definitions of remission and low disease activity. The results show that the SLEDAI and the SLEDAS are of comparable value in assessing SLE activity and complement each other.


  • Open Access

    Giant haematoma of the posterior compartment of thigh in a patient with coronavirus disease 19 pneumonia and pulmonary embolism – Case Report

    by Anna Grzywa-Celińska, Justyna Emeryk-Maksymiuk, Piotr Tarkowski, Adam Krusiński, Katarzyna Redestowicz, Jan Siwiec, Dorota Suszek

    Introduction . During the Coronavirus-19 (Covid-19) pandemic, a significant increase in the frequency of complications in the form of venous thrombosis was observed. However, there is also the other side of the coin – an increase in the tendency to bleeding in the course of COVID19....

  • Open Access

    Differential approach to peripheral blood cell ratios in patients with systemic lupus erythematosus and various manifestations

    by Dorota Suszek, Anna Górak, Maria Majdan

    New markers of systemic lupus erythematosus (SLE) activity are under investigation. In recent years, the researchers have been focusing increased attention on the role of haematological indicators in assessing the disease activity. Specifically, neutrophil-, basophil-, eosinophil-, monocyte- and platelet-to-lymphocyte ratios (NLR, BLR, ELR, MLR and PLR) have been considered. The specific objective of this study was to determine the suitability of the haematological markers for the assessment of SLE activity and SLE-related organ damage. This study is a retrospective analysis of 136 patients with SLE (124 women and 12 men) who received chloroquine/hydroxychloroquine (HQ/HCQ) monotherapy or HQ/HCQ therapy combined with low/medium doses of glucocorticoid. All patients were assessed for disease activity using the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) scale. In addition, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) inflammatory parameters were determined in each patient. NLR, BLR, ELR, MLR and PLR were evaluated and correlated with the SLE activity parameters and inflammatory markers. The mean values of the haematological indicators were compared in particular manifestations of SLE-induced organ damage. For numerical variables, descriptive statistics were calculated: median, standard deviation, minimum and maximum values. The Mann–Whitney U test was used for the comparison of continuous variables in the two groups. The Spearman rank correlation test was used to search for any relationships between variables. A p value < 0.05 was considered to be statistically significant. We have found a positive correlation between ELR, MLR and the SLEDAI scale (r = 0.22 and r = 0.27, respectively). NLR, MLR and PLR ratios were significantly correlated with ESR and CRP. Considerably higher NLR values were found in patients with cutaneous and/or mucosal symptoms and with kidney involvement compared to patients without such involvement (4.26 ± 4.2 vs 3.27 ± 2.7; p = 0.05 and 5.45 ± 5.6 vs 3.05 ± 2.0; p < 0.001 respectively). BLR and MLR were significantly higher in patients manifesting symptoms of vasculitis (0.09 ± 0.1 vs 0.02 ± 0.01; p < 0.001 and 3.1 ± 4.2 vs 0.3 ± 0.1; p < 0.001 respectively), arthritis and/or myositis (0.04 ± 0.09 vs 0.02 ± 0.01; p = 0.01 and 1.02 ± 2.6 vs 0.35 ± 0.4; p = 0.01 respectively), whereas elevated ELR ratios were observed in patients with vasculitis (0.4 ± 0.5 vs 0.08 ± 0.06; p < 0.001) compared to patients without such organ involvement. The PLR marker was substantially higher in patients exhibiting haematological disorders in the course of SLE (276.6 ± 226.4 vs 192.6 ± 133.5; p = 0.01). The results indicate that ELR and MLR are effective markers of SLE activity. The haematological indicators may predict SLE-dependent organ damage, particularly cutaneous, mucosal, arthritic, myositic, haematological and kidney involvement.


    • 1 January 2015
      • Vol. 68  (1) , 104-7

    [Biological treatment in severe Still's disease--a case report].

    by Dorota Suszek, Arkadiusz Koszarny, Radosław Jeleniewicz, Maria Majdan, Anna Bończak, Agnieszka Czukiewska, Barbara Koszła, Sylwia Kurlej, Justyna Markowicz, Agnieszka Szymczyk

    Still's disease and systemic juvenile idiopathic arthritis (JIA) are multisystem inflammatory diseases of unknown etiology, different disease course and prognosis. Still's disease is characterized by hectic fever, arthritis, skin rash, organomegaly, elevated serum ferritin and inflammatory factors. Early diagnosis and intensive treatment can prevent disease progression and reduce complications such as amyloidosis, physical disability. The first choice of treatment are high doses of corticosteroids and synthetic disease-modifying drugs (DMARDs), including methotrexate (MTX), cyclosporine (CsA). Biologic agents are second line therapy when DMARDs aren't effective, e.g. monoclonal antibodies blocking the action of TNF-alpha (anti-TNF-α), interleukin-1 (ANK--anakinra) and interleukin-6 (TCZ--tocilizumab). We describe in details treatment strategies applied in a young woman with severe Still's disease treated with combination therapy of DMARDs and anti-TNF-α, including etanercept (ETA) or certolizumab (CER). TCZ was applied for the treatment of Still's disease following treatment failure with anti-TNF-α. We've achieved a complete remission of the Still's disease during treatment TCZ.

    • 1 January 2015
      • Vol. 68  (3) , 242-7

    Autoantibodies against gliadin in rheumatoid arthritis and primary Sjögren's syndrome patients.

    by Arkadiusz Koszarny, Maria Majdan, Dorota Suszek, Magdalena Dryglewska, Jacek Tabarkiewicz

    Patients with rheumatoid arthritis (RA) and those with primary Sjögren's syndrome (pSS), beside non-specific antibodies, present with organ-specific autoantibodies, including those typical of celiac disease (CD). In the pathogenesis of CD, a role is played by anti-tissue transglutaminase, anti-endomysium, and anti-gliadin (AGA) antibodies. CD can be comorbid with RA and pSS. The aim of the study was to evaluate the prevalence of AGA in RA and pSS patients and discussion of their clinical significance. The study included 121 patients with RA and 30 patients with pSS. IgG AGA were determined by ELISA method. Additionally, the presence of IgG antimitochondrial antibodies (AMA) was determined in all patients. A further observation included patients with AGA. In the RA group, AGA were detected in five patients (4.1%), and in the pSS group - in two patients (6.7%). All patients in the pSS AGA (+) had AMA and autoimmune thyroid disease (AITD). These differences were statistically significant compared to the pSS AGA (-) and AMA (+) group (p=0.002) and the AGA (-) and AITD (+) group (p=0.003). At the time of the study, none of the patients had been diagnosed with CD. AGA, typical of CD, are significantly more frequently detected in patients with RA and pSS than in the general population. The presence of autoantibodies may have an impact on the clinical picture of the disease and further medical procedures. CD testing is warranted in selected patients.


  • Open Access

    Remission in lupus nephritis – report of three cases

    by Dorota Suszek, Anna Wójcik, Maria Majdan

    W pracy przedstawiono przebieg toczniowego zapalenia nerek (TZN) u trzech chorych leczonych agresywnie od początku choroby glikokor­ty­kosteroidami (GKS), cyklofosfamidem (CYC), a następnie mykofeno­lanem mofetylu (MMF). U dwóch chorych potwierdzono IV klasę TZN oraz rozpoznano wtórny zespół antyfosfolipidowy (an­tiphospholipid syndrome – APS). Zastosowanie CYC w terapii in­dukującej remisję oraz MMF w leczeniu podtrzymującym doprowadziło do remisji objawów nerkowych, ale łączyło się z wystąpieniem powikłań infekcyjnych zarówno w czasie leczenia CYC, jak i MMF. Zastosowanie agresywnego leczenia od początku TZN przy uwzględnieniu ryzyka możliwych powikłań daje szansę na osiągnięcie całkowitej remisji choroby.